發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公佈日期，執行董事為李小芳女士（主席）及李燁妮女士；非執行董事為李小羿博士、James Charles Gale先生及黃瑞瑨先 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 李氏大藥廠控股有限公司 | | 股份代號 | 00950 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年十二月三十一日止年度末期股息 | | 公告日期 | 2026年3月30日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 ...

Financial Performance - Revenue for the year ended December 31, 2025, was HKD 1,435,980, representing a 2.6% increase from HKD 1,399,969 in 2024[2] - Gross profit decreased by 3.2% to HKD 729,560 from HKD 753,355 in the previous year[5] - Profit attributable to owners of the company was HKD 91,938, down 1.2% from HKD 93,099 in 2024[2] - Basic and diluted earnings per share were both HKD 15.61, a decrease of 1.3% from HKD 15.81 in 2024[2] - Operating profit for the year was HKD 85,958, a decline from HKD 113,142 in 2024[5] - Total comprehensive income for the year was HKD 378,481, compared to a loss of HKD 394,464 in 2024[6] - The group reported a profit before tax of HKD 72,886,000 for 2025, down from HKD 98,113,000 in 2024, reflecting a decrease of about 25.6%[16] - The group reported a net profit attributable to shareholders of HKD 91,938,000, a slight decrease from HKD 93,099,000 in the previous fiscal year, impacted by increased R&D spending[43] Dividends - The board proposed a final dividend of HKD 0.023 per share, down from HKD 0.025 in the previous year[2] - The group declared an interim dividend of HKD 0.022 per share for 2025, up from HKD 0.020 per share in 2024, totaling HKD 12,954,000[29] - The proposed final dividend for the year ending December 31, 2025, will be payable to shareholders listed as of June 1, 2026[69] Assets and Liabilities - Non-current assets increased to HKD 2,294,569 from HKD 1,833,281, reflecting growth in long-term investments[7] - Current liabilities rose to HKD 1,130,197 from HKD 771,254, indicating increased short-term financial obligations[7] - Total equity attributable to the company's owners increased to HKD 2,045,802,000 in 2025 from HKD 1,651,799,000 in 2024, representing a growth of 23.9%[8] - The company's total liabilities increased to HKD 2,333,660,000 in 2025 from HKD 1,846,612,000 in 2024, marking a rise of 26.4%[8] - The total assets of the group for 2025 amounted to HKD 3,463,857,000, a significant increase from HKD 2,617,866,000 in 2024, representing a growth of about 32.4%[18] Research and Development - Research and development expenses increased to HKD 110,957 from HKD 83,829, indicating a focus on innovation[5] - Research and development expenses for the patented and generic products segment increased to HKD 92,263,000 in 2025 from HKD 62,034,000 in 2024, marking a rise of approximately 48.7%[16] - The group invested a total of HKD 359,812,000 in R&D activities, which accounted for 25.1% of annual revenue, a significant increase from 13.8% in the previous fiscal year[41] Market and Sales - Over 90% of the group's revenue in 2025 was derived from operations in the People's Republic of China, highlighting the market's significance[20] - The group's revenue from the patented and generic products segment for 2025 was HKD 871,645,000, an increase from HKD 846,732,000 in 2024, representing a growth of approximately 2.5%[16] - The revenue from the introduced products segment for 2025 was HKD 564,335,000, up from HKD 553,237,000 in 2024, indicating a growth of about 2.0%[16] - Sales from introduced products amounted to HKD 564,335,000, accounting for 39.3% of total revenue, while sales from patented and generic products contributed HKD 871,645,000, or 60.7% of total revenue[36] Corporate Governance - The company has adopted the standard code of conduct for securities trading by directors as per the listing rules for the year ending December 31, 2025[71] - The company has complied with the corporate governance code as per the listing rules for the year ending December 31, 2025[72] - The board will continue to review the company's corporate governance practices to ensure compliance with the corporate governance code[73] Future Outlook - The company anticipates continued revenue growth into the fiscal year 2026, despite industry challenges, maintaining a cautiously optimistic outlook[60] - The company is committed to cost control and operational efficiency, ensuring prudent resource allocation and strict management of unnecessary expenses[62] - Research and development investments will focus on projects with clear commercial prospects, exploring licensing opportunities to create additional revenue streams[63] Production and Operations - The manufacturing facilities have improved production capacity and efficiency, achieving a 10% increase in total output for the fiscal year 2025, with pre-filled syringe production rising by 18%[44] - The company is expanding the production scale of the Aripiprazole tablets and has successfully advanced the verification batch production of the fentanyl aerosol inhaler after Phase II clinical trials[45] - The new manufacturing facility in Fremont is a strategic focus, recently starting production of process performance qualification batches, which could become a significant profit growth engine[63] Regulatory Approvals - The FDA approved the supplemental new drug application for ADASUVE® on December 29, 2025, allowing the relocation of commercial manufacturing facilities to Fremont, California, thus diversifying the production network[47] - The company has received regulatory approval for the Cyprofloxacin ear drops, used for treating acute otitis externa and in conjunction with ventilation tube treatment for acute otitis media[54]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Lee's Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司 * （於開曼群島註冊成立之有限公司） （股份代號：950） 自願性公佈 茵若颯取得國家藥監局批准 本 公 佈 由 李 氏 大 藥 廠 控 股 有 限 公 司（「本公司」或「李氏大藥廠」，連 同 其 附 屬 公 司 稱 為「本集團」）董 事（「董 事」）會（「董事會」）自 願 作 出。 本 公 司 董 事 會 欣 然 宣 佈，於 二 零 二 六 年 三 月 十 七 日，中 國 國 家 藥 品 監 督 管 理 局 （「國家藥監局」）已 批 准 茵 若 颯（由Cosette Pharmaceuticals擁有並已授予李氏大藥廠 許 可）用 於 治 療 具 有 中 重 度 症 狀（不 包 括 泌 尿 系 症 狀）的 絕 經 後 女 性 外 陰 陰 道 萎 縮 ...

香港，二零 二 六 年 三 月 十 七 日 (股份代號：950) 董事會會議公告 本 公 佈 乃 根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則 第 13.43 條作出。 李氏大藥廠控股有限公司 ( 「 本公司 」 ) 董事會 ( 「 董 事 會 」 ) 謹此宣佈， 本 公 司 董 事 會 會 議 將 於 二 零 二 六 年 三 月 三 十 日 ( 星 期 一 ) 於 香 港 新 界 沙 田 香 港 科 學 園第三期科技大道東 20E 大 樓 1 樓 舉行，為審議 ( 其 中 包 括 ) 並 批 准 ( 如 認 為 合 適 ) 刊 發 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 五 年 十 二 月三十 一 日 止 年 度 的 年 度 業績公 佈 及 考 慮 建 議 末 期 股 息 ( 如 有 ) 。 承董事會命 李氏大藥廠控股有限公司 主 席 李小芳 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 的 內 容 概 不 負 責 ， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明 ， 並 明 ...

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 本月底法定/註冊股本總額： HKD 50,000,000 FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 公司名稱: 李氏大藥廠控股有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00950 | 說明 | | 李氏大藥廠控股有限公司 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 李氏大藥廠控股有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00950 | 說明 | | 李氏大藥廠控股有限公司 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 ...

Group 1 - The company, Lee's Pharmaceutical (00950), announced that its supplemental new drug application for ADASUVE has been approved by the FDA on December 29, 2025 [1] - The approval allows the commercial production facility for ADASUVE to be relocated from Mountain View, California, to Fremont, California [1] - The application was submitted to the FDA on August 29, 2025, by the original owner, and the company's wholly-owned subsidiary, Nova Pneuma Incorporated (NPI), acquired the relevant assets in December 2025 [1] Group 2 - The FDA approval marks a significant regulatory milestone for the group and indicates that the regulatory requirements related to the acquisition of the company's first pharmaceutical facility in the U.S. have been fulfilled [2] - The board believes that this approval supports the group's strategy to expand its innovative drug delivery technology portfolio based on the Staccato platform, which has the potential for application in various therapeutic indications [2] - This development aligns with the company's global expansion strategy and its ongoing commitment to regulatory compliance and drug quality [2]

Core Viewpoint - The approval of the supplemental new drug application for ADASUVE® by the FDA marks a significant regulatory milestone for the company, facilitating the commercial production of the product in the U.S. [1][2] Group 1: FDA Approval and Production - The FDA approved the supplemental new drug application for ADASUVE® on December 29, 2025, allowing the commercial production facility to be relocated from Mountain View, California, to Fremont, California [1] - The application was originally submitted to the FDA on August 29, 2025, by the previous owner, and the company's wholly-owned subsidiary, Nova Pneuma Incorporated (NPI), acquired the relevant assets in December 2025 [1] Group 2: Strategic Implications - The FDA approval signifies the completion of regulatory requirements associated with the company's first pharmaceutical facility acquisition in the U.S. [2] - The board believes this approval supports the company's strategy to expand its innovative drug delivery technology portfolio based on the Staccato® platform, which has the potential for application in various therapeutic indications [2]

Core Viewpoint - The approval of the supplemental new drug application for ADASUVE by the FDA marks a significant regulatory milestone for the company, facilitating the commercial production of the drug in the U.S. [1][2] Group 1: FDA Approval and Production - The FDA approved the supplemental new drug application for ADASUVE on December 29, 2025, allowing the commercial production facility to be relocated from Mountain View, California, to Fremont, California [1] - The application was submitted to the FDA on August 29, 2025, by the original owner, and the company's wholly-owned subsidiary, Nova Pneuma Incorporated, acquired the relevant assets in December 2025 [1] Group 2: Strategic Implications - The FDA approval signifies the completion of regulatory requirements related to the company's first pharmaceutical facility acquisition in the U.S. [2] - The board believes this approval supports the company's strategy to expand its innovative drug delivery technology portfolio based on the Staccato platform, which has the potential for application in various therapeutic indications [2] - This development aligns with the company's global expansion strategy and its commitment to regulatory compliance and drug quality [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Lee's Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司 * （於開曼群島註冊成立之有限公司） （股份代號：950） 自願性公佈 FDA批 准《ADASUVE®》的 補 充 新 藥 上 市 申 請 本 公 佈 由 李 氏 大 藥 廠 控 股 有 限 公 司（「本公司」或「李氏大藥廠」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事（「董 事」）會（「董事會」）自 願 作 出。 本 公 司 董 事 會 欣 然 宣 佈，《ADASUVE®》（洛 沙 平 吸 入 粉 劑，一 種 單 劑 量、單 次 使 用 的 藥 械 組 合 產 品）的 補 充 新 藥 上 市 申 請（「補充新藥申請」）已 於 二 零 二 五 年 十 二 月 二 十 九 日 獲 美 國 食 品 藥 品 監 督 管 理 局（「FDA」）批 准 ...